A randomized, double-blind, placebo-controlled, multicenter, multinational, phase II trial of L-BLP25 in patients with colorectal carcinoma following R0/R1 hepatic metastasectomy. Background: There ...

Pelareorep combined with FOLFIRI and bevacizumab produced a 19.5-month median duration of response and 33% ORR in second-line ...

Inhibrx Biosciences (NASDAQ:INBX) shared a clinical update on ozekibart in advanced colorectal cancer, highlighting Phase I/II data evaluating ozekibart in combination with FOLFIRI in a heavily pretre ...

Phase II study of E7820 in combination with cetuximab in subjects (pts) with metastatic and refractory colorectal cancer (CRC). Background: Motesanib is an oral inhibitor of VEGF, PDFG, and Kit ...

Inhibrx Biosciences recently reported updated interim Phase 1/2 data showing that ozekibart (INBRX-109) plus FOLFIRI produced a 20% objective response rate, 5.5-month median progression-free survival ...

Please provide your email address to receive an email when new articles are posted on . The study, presented at ASCO Annual Meeting, evaluated intermittent vs. continuous panitumumab (Vectibix, Amgen) ...

Shares of Inhibrx Biosciences INBX rallied 36.9% on Wednesday. The massive surge was triggered by encouraging updated interim ...

- Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in ...

Gastric cancer imposes a considerable health burden worldwide, accounting for ∼700,000 deaths every year. The disease is often diagnosed at advanced stages and has a poor prognosis. Many chemotherapy ...

Adding oxaliplatin to a chemotherapy regimen already used in combination with bevacizumab (Avastin) for the treatment of metastatic colorectal cancer has been shown to double the 5-year survival rate.